Semaglutides success stories extend far beyond the controlled settings of clinical trials
Throat lozenges and sprays can provide localized relief by numbing the throat and soothing irritation
Emerging multimodal biomarkers, genetic risk (e.g., APOE4, LRRK2, TREM2), metabolic status (insulin resistance, diabetes), imaging (amyloid/tau PET, MRI), and fluid omics (CSF proteomics, metabolomics), could be integrated into companion-diagnostic frameworks as in oncology
Some patients experience gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation when they start semaglutide, even if they tolerated tirzepatide
However, six participants were maintained on a reduced dose of semaglutide because of AEs (1.7 mg, n = 1